Novo Nordisk Teams With Aspect Biosystems On Diabetes Cell Therapy
Aspect says its bioprinted tissue therapeutics include immune-resistant encapsulation, which Novo Nordisk hopes will offer a safer approach to type 1 diabetes cell therapy.
You may also be interested in...
Sanofi paid $2.9bn for Tzield and its developer Provention earlier this year, but a mixed readout in its key Phase III study will raise doubts among analysts about its long-term prospects in later-stage patients.
Launched with an ambitious R&D vision for cell therapies two years ago, Sana is now having to narrow its focus while it awaits the first of its Phase I readouts.
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.